Effects of risedronate on fracture risk in postmenopausal women with osteopenia

Osteoporosis International

Volumn 19, Issue 5, 2008, Pages 681-686

  Siris, E S ^a   Simon, J A ^b   Barton, I P ^c   McClung, M R ^d   Grauer, A ^c  

^a NewYork Presbyterian Hospital   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Bisphosphonates; Fragility fracture; Nonvertebral fracture; Osteopenia; Risedronate; Vertebral fracture

Indexed keywords

PLACEBO; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE MASS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; POST HOC ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK FACTORS;

EID: 43149103935     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0493-y     Document Type: Article

References (32)

1. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
2. Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195-202
3. Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787-2793
4. Sornay-Rendu E, Munoz F, Garnero P et al (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813-1819
5. Sanders KM, Nicholson GC, Watts JJ et al (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38:694-700
6. America's bone health: The state of osteoporosis and low bone mass in our nation (2002) National Osteoporosis Foundation, Washington, DC
7. Bone Health and Osteoporosis (2004) U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group (1994) World Health Organ Tech Rep Ser 843:1-129
9. Prevention and Management of Osteoporosis (2003) Geneva: World Health Organization, Technical Report Series, Vol. 921
10. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis (1998) WHO Technical Bulletin: World Health Organization
11. Miller PD, Barlas S, Brenneman SK et al (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164:1113-1120
12. Physician's Guide to Prevention and Treatment of Osteoporosis (2003) National Osteoporosis Foundation, Washington, DC
13. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936
14. Kanis JA, Oden A, Johnell O et al (2002) Uncertain future of trials in osteoporosis. Osteoporos Int 13:443-449
15. Fogelman I, Ribot C, Smith R et al (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895-1900
16. McClung MR, Bensen WG, Bolognese MA et al (1998) Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass. Osteoporos Int 8:111
17. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
18. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
19. Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33:293-300
20. Quandt SA, Thompson DE, Schneider DL et al (2005) Effect of alendronate on vertebral fracture risk in women with bone mineral density T-score from -1.6 to -.2.6 at the femoral neck: The Fracture intervention trial. Mayo Clin Proc 80:343-349
21. Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108-1112
22. Roux C, Seeman E, Eastell R et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433-439
23. Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135
24. Heaney RP, Zizic TM, Fogelman I et al (2002) Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13:501-505
25. Black D, Thompson D, Quandt S et al (2002) Alendronate reduces risk of vertebral fracture in women with BMD t-scores above -2.5: results from the Fracture Intervention Trial (FIT). J Bone Miner Res 17:S474
26. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
27. McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dewlling elderly women unselected for osteoporosis: Results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135-141
28. Dufresne TE, Chmielewski PA, Manhart MD et al (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423-432
29. Borah B, Dufresne TE, Chmielewski PA et al (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736-746
30. Borah B, Dufresne TE, Chmielewski PA et al (2002) Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17:1139-1147
31. Borah B, Ritman EL, Dufresne TE et al (2004) Sustained effect of risedronate on trabecular architecture and mineralization over 5 years of treatment: triple biopsy studies by micro-CT. European Symposium on Calcified Tissues, Nice, France, June 5-9
32. Kanis JA, Johnell O, Oden A et al (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis Int 12:989-995